VEGF receptor signaling in tumor angiogenesis

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 3-10

  McMahon, Gerald ^a  

^a SUGEN INC   (United States)

Author keywords

Angiogenesis; Tyrosine kinase inhibitors; Tyrosine kinase receptors; Vascular endothelial growth factor (VEGF)

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER GROWTH; CONFERENCE PAPER; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0034000699     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-3     Document Type: Conference Paper

References (92)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
3. Pepper MS, Montesano R, Mandriota SJ et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996;49:138-162.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
5. Norrby K. Angiogenesis: new aspects relating to its initiation and control. APMIS 1997;105:417-437.
6. Polverini PJ. How ihe extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer 1996;32A:2430-2437.
7. Brem S, Brem H, Folkman J et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-2812.
8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
9. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989;109:1-6.
10. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994;145:1023-1029.
11. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88:1146-1151.
12. Jouanneau J, Moens G, Montesano R et al. FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Growth Factors 1995;12:37-47.
13. Suri C, McClain J, Thurston G et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-471.
14. Pepper MS, Vassalli JD, Orci L et al. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993;204:356-363.
15. Gleave ME, Hsieh JT, Wu HC et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 1993;53:5300-5307.
16. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
17. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
18. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
19. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
20. Meyer M, Clauss M, Lepple-Wienhues A et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999;18:363-374.
21. Ogawa S, Oku A, Sawano A et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273:31273-31282.
22. Potgens AJ, Eubsen NH, van Altena MC et al. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem 1994;269:32879-32885.
23. Tischer E, Gospodarowicz D, Mitchell R et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989;165:1198-1206.
24. McDonald NQ, Hendrickson WA. A structural superfamily of growth factors containing a cystine knot motif. Cell 1993;73:421-424.
25. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
26. Torimura T, Sata M, Ueno T et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-991.
27. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-1478.
28. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
29. Phillips GD, Stone AM, Jones BD et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994;8:961-965.
30. Tolentino MJ, Miller JW, Gragoudas ES et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964-970.
31. Cao Y, Linden P, Farnebo J et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998;95:14389-14394.
32. Alon T, Hemo I. Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
33. Bell C, Lynam E, Landfair DJ et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999;35:533-542.
34. Kieser A, Weich HA, Brandner G et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-969.
35. Grugel S, Finkenzeller G, Weindel K et al. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919.
36. Graeven U, Fiedler W, Karpinski S et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-I and KDR. J Cancer Res Clin Oncol 1999;125:621-629.
37. Shweiki D, Itin A, Softer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
38. Minchenko A, Bauer T, Salceda S et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994;71:374-379.
39. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
40. Ikeda E, Achen MG, Breier G et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-19766.
41. Liu Y, Cox SR, Morita T et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-643.
42. Takagi H, King GL, Robinson GS et al. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci 1996;37:2165-2176.
43. Hashimoto E, Ogita T, Nakaoka T et al. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267:H1948-H1954.
44. Gu JW, Adair TH. Hypoxia-induced expression of VEGF is reversible in myocardial vascular smooth muscle cells. Am J Physiol 1997;273:H628-H633.
45. Partovian C, Adnot S, Eddahibi S et al. Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension. Am J Physiol 1998;275:H1948-H1956.
46. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997;3:158-164.
47. Liu B, Earl HM, Baban D et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995;217:721-727.
48. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
49. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-898.
50. Breier G, Albrecht U, Sterrer S et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992;114:521-532.
51. Jakeman LB, Armanini M, Phillips HS et al. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993;133:848-859.
52. Hubbard SR. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 1999;71:343-358.
53. Strawn LM, Shawver LK. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opinion on Investigational Drugs 1998;7:553-573.
54. Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846.
55. Quinn TP, Peters KG, De Vries C et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993;90:7533-7537.
56. Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-579.
57. Bernatchez PN, Soker S, Sirois MG. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 1999;274:31047-31054.
58. Kurebayashi J, Otsuki T, Kunisue H et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999;90:977-981.
59. Shaheen RM, Davis DW, Liu W et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-5416.
60. Yoshiji H, Kuriyama S, Hicklin DJ et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999;30:1179-1186.
61. Droller MJ. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol 1998;160:1932.
62. Kitamura M, Toi M, Arai K et al. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep 1998;5:1419-1424.
63. Balbay MD, Pettaway CA, Kuniyasu H et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 1999;5:783-789.
64. Parry TJ, Cushman C, Gallegos AM et al. Bioactivity of antiangiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999;27:2569-2577.
65. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
66. Borgstrom P, Hillan KJ, Sriramarao P et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
67. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996;56:921-924.
68. Lin P, Sankar S, Shan S et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
69. Prewett M, Huber J, Li Y et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218.
70. Fong TAT, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
71. Angelov L, Salhia B, Roncari L et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 1999;59:5536-5541.
72. Hennequin LF, Thomas AP, Johnstone C et al. The design and synthesis of a novel, orally active VEGF receptor tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 1999;40:69a.
73. Ogilvie DJ, Wedge SR, Dukes M et al. ZD4190: an orally administered inhibitor of VEGF signaling with pan-xenograft anti-tumor activity. Proc Am Assoc Cancer Res 1999;40:69a.
74. Wedge SR, Waterton JC, Tessier JJ et al. Effect of the VEGF receptor tyrosine kinase inhibitor ZD4190 on vascular endothelial permeability. Proc Am Assoc Cancer Res 1999;40:415a.
75. Xu L, Herrera CA, Yoneda J et al. Therapy of VEGF-dependent human ovarian carcinoma by oral administration of CGP 79787/ZK222584, an inhibitor of the VEGF receptor tyrosine kinase. Proc Am Assoc Cancer Res 1999;40:457a.
76. Belletti B, Ferraro P, Arra C et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 1999;18:4860-4869.
77. Shih SC, Mullen A. Abrams K et al. Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem 1999;274:15407-15414.
78. Oku T, Tjuvajev JG, Miyagawa T et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 1998;58:4185-4192.
79. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
80. Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999;90:93-100.
81. Wang G, Dong Z, Xu G et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 1998;124:615-620.
82. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
83. Gordon M, Talpaz M, Margolin K et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients (pts) with metastatic cancer. Proc Am Soc Clin Oncol 1998;17:211a.
84. Reese D, Frohlich M, Bok R et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhumAb) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999;18:351a.
85. Goldman CK, Kendall RL, Cabrera G et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-8800.
86. Sun L, Tran N, Liang C et al. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999;42:5120-5130.
87. Hamby JM, Showalter HDH. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:169-193.
88. Rosen L, Mulay M, Mayers A et al. Phase 1 dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. J Clin Oncol 1999;18:161a.
89. Scigalla P, Hannah A, Langecker P et al. First preclinical and clinical results with the antiangiogenetic substance SU5416 in malignancies. Eur J Cancer 1999;35(suppl 5):S62a.
90. Shawver LK, Strawn LM, Fong TAT et al. SU6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties. Proc Am Assoc Cancer Res 1999;40:723a.
91. Liang C, Sun L, Tran N et al. Discovery and design of angiogenesis inhibitors that inhibit tyrosine kinase activities associated with VEGF, FGF, and PDGF receptors. Proc Am Assoc Cancer Res 1999;40:68a.
92. Fabbro D, Buchdunger E, Wood J et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.